PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1138
https://www.valueinhealthjournal.com/article/S1098-3015(19)33516-8/fulltext
Title :
PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33516-8&doi=10.1016/j.jval.2019.09.1138
First page :
Section Title :
Open access? :
No
Section Order :
10997